These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
682 related articles for article (PubMed ID: 23286431)
1. Which is the optimal antihypertensive combination in different diseases, a renin- angiotensin-aldosterone system inhibitor with a diuretic or with a calcium channel blocker? Riva N; Lip GY Curr Pharm Des; 2013; 19(21):3753-65. PubMed ID: 23286431 [TBL] [Abstract][Full Text] [Related]
2. Combination therapy as first-line treatment for hypertension. Crawford MH Am J Cardiovasc Drugs; 2009; 9(1):1-6. PubMed ID: 19178127 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan. da Silva PM Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210 [TBL] [Abstract][Full Text] [Related]
4. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients. Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757 [TBL] [Abstract][Full Text] [Related]
5. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. Jamerson K; Weber MA; Bakris GL; Dahlöf B; Pitt B; Shi V; Hester A; Gupte J; Gatlin M; Velazquez EJ; N Engl J Med; 2008 Dec; 359(23):2417-28. PubMed ID: 19052124 [TBL] [Abstract][Full Text] [Related]
6. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial. Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578 [TBL] [Abstract][Full Text] [Related]
7. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Volpe M; Tocci G Vasc Health Risk Manag; 2012; 8():371-80. PubMed ID: 22745561 [TBL] [Abstract][Full Text] [Related]
8. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner. Roberts ME; Epstein BJ J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098 [TBL] [Abstract][Full Text] [Related]
9. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial. Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421 [TBL] [Abstract][Full Text] [Related]
10. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Bramlage P Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001 [TBL] [Abstract][Full Text] [Related]
11. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention. Talbert RL J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609 [TBL] [Abstract][Full Text] [Related]
13. Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials. Reboldi G; Gentile G; Angeli F; Verdecchia P Vasc Health Risk Manag; 2009; 5(1):411-27. PubMed ID: 19475778 [TBL] [Abstract][Full Text] [Related]
14. Prospective randomized study of the tolerability and efficacy of combination therapy for hypertensive chronic kidney disease: results of the PROTECT-CKD study. Hayashi M; Uchida S; Kawamura T; Kuwahara M; Nangaku M; Iino Y; Clin Exp Nephrol; 2015 Oct; 19(5):925-32. PubMed ID: 25680887 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with Renin-Angiotensin-aldosterone receptor blockers for hypertension: how far have we come? Weir MR; Bakris GL J Clin Hypertens (Greenwich); 2008 Feb; 10(2):146-52. PubMed ID: 18256579 [TBL] [Abstract][Full Text] [Related]
16. Cochrane in context: pharmacological interventions for hypertension in children. Chaturvedi S; Lipszyc DH; Licht C; Craig JC; Parekh RS Evid Based Child Health; 2014 Sep; 9(3):581-3. PubMed ID: 25236306 [TBL] [Abstract][Full Text] [Related]
17. Management of hypertension with fixed-dose triple-combination treatments. Epstein BJ; Shah NK; Borja-Hart NL Ther Adv Cardiovasc Dis; 2013 Oct; 7(5):246-59. PubMed ID: 23945906 [TBL] [Abstract][Full Text] [Related]
18. Hypertension management: rationale for triple therapy based on mechanisms of action. Neutel JM; Smith DH Cardiovasc Ther; 2013 Oct; 31(5):251-8. PubMed ID: 23121769 [TBL] [Abstract][Full Text] [Related]
19. Update on the management of hypertension: recent clinical trials and the JNC 7. Moser M J Clin Hypertens (Greenwich); 2004 Oct; 6(10 Suppl 2):4-13. PubMed ID: 15470293 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy in hypertension: what are the best options according to clinical pharmacology principles and controlled clinical trial evidence? Taddei S Am J Cardiovasc Drugs; 2015 Jun; 15(3):185-94. PubMed ID: 25850749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]